MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2
Authors Yu LX, Zhang BL, Yang MY, Liu H, Xiao CH, Zhang SG, Liu R
Received 29 January 2019
Accepted for publication 20 April 2019
Published 15 July 2019 Volume 2019:12 Pages 5639—5647
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Carlos E Vigil
Ling-Xiang Yu,1,2 Bo-Lun Zhang,3 Mu-Yi Yang,2 Hu Liu,2 Chao-Hui Xiao,2 Shao-Geng Zhang,2 Rong Liu1
1Departments of Surgical Oncology, Chinese People’s Liberation Army General Hospital, Beijing 100039, People’s Republic of China; 2Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, People’s Republic of China; 3Department of General Surgery, Clinical Medical College of Weifang Medical University, Weifang 261053, People’s Republic of China
Background: A recent study has revealed that miR-106b-5p might promote hepatocellular carcinoma (HCC) stemness maintenance and metastasis by targeting PTEN via PI3K/Akt pathway based on HCC cell lines and animal models. Its clinical relevance remains unknown.
Purpose: Herein, we aimed to evaluate associations of miR-106b-5p dysregulation with various clinicopathological features of HCC patients and investigate its functions during HCC progression.
Patients and methods: At first, miR-106b-5p expression in 130 pairs of HCC and adjacent normal liver tissues was detected by quantitative PCR. Chi-square test was then performed to determine clinical significance. Further investigations on its functions were performed by miRNA target prediction and validation, as well as cellular experiments.
Results: miR-106b-5p levels in HCC tissues were significantly higher than those in the adjacent normal liver tissues (P<0.001). High miR-106b-5p expression was significantly associated with advanced tumor stage (P=0.02) and high tumor grade (P=0.03). In addition, Friend of GATA 2 (FOG2) was identified as a direct target of miR-106b-5p in HCC cells. Moreover, the clinical relevance to HCC progression of the combined high miR-106b-5p and low FOG2 expression was more significant than high miR-106b-5p alone. Functionally, enforced expression of miR-106b-5p reduced FOG2 expression and promoted the proliferation and invasion of HCC cells. Furthermore, co-transfection of FOG2 restored the oncogenic roles of miR-106b-5p over-expression.
Conclusion: Our data offer the convincing evidence that miR-106b-5p upregulation may promote the aggressive progression of HCC. miR-106b-5p overexpression may promote HCC cell proliferation and invasion by suppressing FOG2, implying its potentials as a promising therapeutic target for HCC patients.
Keywords: hepatocellular carcinoma, microRNA-106b-5p, friend of GATA 2, tumor progression, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]